[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of the Pacific\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":128},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,78,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100560196","the-effect-of-intraoral-transcutaneous-electrical-nerve-stimulation-in-orthodontics-pain-100560196",false,"NCT06573996","The Effect of Intraoral Transcutaneous Electrical Nerve Stimulation in Orthodontics Pain","The Effect of Intraoral Transcutaneous Electrical Nerve Stimulation (TENS) on Pain Perception During Orthodontic Alignment and Leveling: A Randomized Clinical Trial","Inclusion Criteria:\n\nGeneral Health: Patients who are generally healthy.\n\nOrthodontic Treatment: Patients undergoing orthodontic treatment that requires the use of full-fixed appliances.\n\nNo Pain Medication: Patients not currently taking any medications for pain management.\n\nExclusion Criteria:\n\nPatients with a history of seizures\n\nPatients with or with a history of cardiac arrhythmias or pacemaker treatment\n\nPatients taking any over-the-counter or prescription pain medication during the testing period.",true,"ALL","12 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to determine whether an intraoral Transcutaneous Electrical Nerve Stimulation (TENS) device can reduce pain during orthodontic alignment and leveling in adolescents and adults. The study aims to compare the effectiveness of the TENS device in reducing pain on one side of the mouth, where the device is used, to the other side, where a non-functioning (placebo) device is applied.\n\nThe primary questions this study aims to answer are:\n\nDoes the TENS device effectively reduce pain during orthodontic treatment compared to the placebo? How do patients pain levels differ between the treated and untreated sides of the mouth?\n\nParticipants will:\n\nHave an orthodontic appliance placed on their teeth. Experience the TENS device being applied to one side of their mouth for 2.5 minutes immediately after the appliance placement (brackets and wires).\n\nReport their pain levels at various intervals after the procedure (immediately, 2 hours, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours).\n\nThis study includes up to 150 participants who are undergoing routine orthodontic treatment. The findings will help researchers understand whether the TENS device can effectively reduce discomfort during orthodontic procedures, potentially leading to better patient care and comfort.",[27,28,29,30],"Orthodontic Appliance","Pain","Transcutaneous Electric Nerve Stimulation","Orthodontic Appliance Complication",[32,33,34,35,36,37],"Orthodontic Pain","TENS Therapy","Orthodontic Alignment","Randomized Clinical Trial","Transcutaneous Electrical Nerve Stimulation (TENS)","Dental Pain Eraser","RECRUITING","2026-02-11",{"date":41,"type":42},"2026-02-17","ACTUAL",{"date":44,"type":42},"2024-09-16",{"date":46,"type":21},"2029-09-01",{"name":48,"class":49},"University of the Pacific","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":16,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":50},"100609301","phase-4-effects-of-energy-drinks-on-cardiovascular-endpoints-100609301","NCT07212803","Effects of Energy Drinks on Cardiovascular Endpoints","Evaluation of Energy Drinks on Electrocardiographic Parameters: A Randomized, Double Blind, Controlled, Crossover, Proof-of-concept Study","Inclusion Criteria:\n\n* Healthy male or female adults 18-40 years of age\n* Female participants of child-bearing potential must have a negative pregnancy test at the baseline visit\n* Participants must be willing to refrain from caffeine and alcohol use 72 hours prior to sessions on study days\n* Participants must be willing and able to: (1.) Consume up to 1 liter of fluid within a 30-minute period per visit (2.) Swallow a single large capsule per visit\n* Participants must be willing to fast 10 hours prior to sessions on study days (only water is allowed during the fasting and active study period)\n* Participants must have active health insurance throughout the duration of the study\n\nExclusion Criteria:\n\n* Have a corrected QT (QTc) interval greater than 450 milliseconds (ms) for males or greater than 470 milliseconds (ms) for females, determined during the baseline visit\n* Presence of any known medical condition, confirmed through participant interview. Examples of these include but not limited to: Dyslipidemia, Thyroid disease, Diabetes, Recurrent headache, Any psychiatric condition or neurological disorder, History of alcohol or drug abuse, Past diagnosis or history of renal insufficiencies, Hepatic dysfunction, Electrolyte imbalances requiring hospitalization\n* Presence of any known heart\u002Fcardiac diseases or conditions such as: Atrial Fibrillation, History of stroke or heart attack, Hypertension, Heart Failure, Vascular Disease, Family history\u002FActive Long QT Syndrome, Coronary artery disease, Cardiomyopathy, Valvular heart disease, Ventricular arrhythmia, Congenital heart defect, Pericardial disease, Myocarditis\n* Study physician recommendation for participant to not be enrolled.\n* Are underweight (BMI\\\u003C18.5 kg\u002Fm2, CDC 2024), have poor eating habits resulting in poor weight control, or have any factors that will put the participant at risk from fasting.\n* Have any contraindications to the use of moxifloxacin, including a past medical history of myasthenia gravis, QT prolongation, or hypersensitivities and allergic reactions to moxifloxacin or any other fluoroquinolone antibiotics\n* Pre-existing risk to tendinitis and tendon rupture, peripheral neuropathy, or central nervous system side effects\n* Concurrent use of ANY medication taken daily including herbal products or supplements (daily basis is defined as greater than 2 days per week)\n* Self-reported allergy to taurine\n* Self-reported allergy to nuts (peanuts, pecans, cashews, etc.)\n* Self-reported allergic reaction to the adhesive pads (electrodes, continuous glucose monitors, etc.)\n* Fear of needle puncture\n* Smokers using cigarettes, vaporized nicotine, or marijuana products currently or within the past month\n* Current usage of any nicotine or tobacco products including but not limited to intranasal, sublingual, oral, or transdermal dosage forms\n* Currently pregnant or breastfeeding\n* Have a positive pregnancy test during the baseline visit\n* Are currently enrolled in any other clinical study or have participated in another study within the last 30 days\n* Non-English speaking\u002Freading individuals will be excluded due to the unavailability of medically qualified translators throughout all study procedures\n* If the candidate does not sign the informed consent document","18 Years","40 Years",{"count":61,"type":21},3,[63],"PHASE4","This is a clinical trial looking at the impact of energy drinks on heart related parameters. The study will enroll 3 participants who will be exposed to 8 different interventions.",[66,67],"Healthy Volunteers","Safety After Oral Intake",[69],"Energy Drinks","2025-11-20",{"date":72,"type":42},"2025-11-26",{"date":74,"type":42},"2025-11-01",{"date":76,"type":21},"2026-09",{"name":48,"class":49},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":50},"100501974","phase-3-topical-treatment-for-tmj-arthralgia-100501974","NCT05816226","Topical Treatment for TMJ Arthralgia","Comparison of Topical 1% Diclofenac and Topical 2.5% Hydrocortisone for TMJ Arthralgia","Inclusion Criteria:\n\n* Arthralgia of at least 1 TMJ for at least 3 days\n\nExclusion Criteria:\n\n* Systemic pain condition\n* Past adverse reaction to steroid\n* Currently taking steroid\n* Taken steroid in the past \\_\\_\\_ months\n* Muscle relaxants (may start after study is complete)\n* New night guard during study, or within 1 month of start of study (may start after study is complete)",{"count":86,"type":21},90,[88],"PHASE3","The goal of this clinical trial is to evaluate the efficacy of topical 2.5% hydrocortisone in TMJ arthralgia. The main questions it aims to answer are:\n\n* How does pain reduction compare?\n* How does improvement in jaw function limitation compare?\n* How do side effects compare? Participants will\n* On day 1 be examined and report their pain level and jaw function limitation\n* On days 1-21, apply their cream four times a day\n* On day 21, report their pain level, jaw function limitation, compliance with instructions, and side effects.\n\nResearchers will compare topical 2.5% hydrocortisone and topical 1% diclofenac to see if efficacy and side effects differ.",[91],"TMJ Pain",[93,94,95,96],"diclofenac","hydrocortisone","TMJ","arthralgia","2024-12-05",{"date":99,"type":42},"2024-12-11",{"date":101,"type":42},"2023-06-01",{"date":103,"type":21},"2026-04",{"name":48,"class":49},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":50},"100547967","effects-of-invisalign-palatal-expander-system-100547967","NCT06414863","Effects of Invisalign Palatal Expander System","Treatment Effects of Invisalign Palatal Expander System and Hyrax Palatal Expander - A Randomized Controlled Trial","Inclusion criteria:\n\n1. Mixed dentition phase with at least three nonmobile (stable) teeth which have more than 1\u002F4 of primary molar root length left16 in either side\n2. Early permanent dentition stage and early permanent dentition but second permanent molars not yet fully erupted in the arch\n3. Unilateral or bilateral posterior cross bite patients; or Patients who have been diagnosed with transverse maxillary deficiency (Skeletal transverse discrepancy measured from the estimated center of resistances of the first molars17 ≤ - 3 mm);\n4. Patients with Class I or Class II skeletal relationship\n5. Subjects willing to consent to the trial\n\nExclusion Criteria:\n\n1. Any general medical health problems which may influence treatment\n2. Any craniofacial anomalies\n3. Skeletal Class III patients\n4. Mixed dentition patients with more than 2 heavily restored primary second or permanent first molars.","6 Years","14 Years",{"count":115,"type":21},120,[24],"The aim of this study is to evaluate the effectiveness of Invisalign Palatal Expander system ingrowing patients. This study compares the treatment outcomes of Invisalign Palatal Expander system to conventional treatments through randomized controlled trial.",[119],"Palatal Expansion Technique","2024-05-13",{"date":122,"type":42},"2024-05-16",{"date":124,"type":21},"2024-05-10",{"date":126,"type":21},"2034-05-10",{"name":48,"class":49},""]